BPC-157 + TB-500 ("Wolverine"): What Is Actually Known
Also known as: BPC-157 + TB-500 · Wolverine · Wolverine stack · Wolverine blend · BPC/TB · BPC-157 + Thymosin Beta-4
Widely called the "Wolverine stack", this pairs the two most popular repair peptides on the assumption that they work through different mechanisms and therefore complement each other. The reasoning is coherent: BPC-157 is associated in animal work with angiogenesis and tendon-to-bone healing, while TB-500 relates to actin regulation and cell migration. What has to be said plainly is that neither compound has published human efficacy trials for injury repair, and the combination has never been tested in humans at all. The animal literature is genuinely interesting; it is not the same thing as evidence in people. Educational only, not medical advice.
Why they are paired
The rationale is mechanistic non-overlap. BPC-157, a synthetic fragment derived from a protein found in gastric juice, is associated in rodent studies with new blood-vessel formation and with tendon and ligament healing — including the difficult tendon-to-bone junction. TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin sequestration, which governs how cells build their internal scaffolding and migrate to a wound.
Put simply: one is argued to improve blood supply to the repair site, the other to help the cells doing the repairing get there and reorganise. If both were true in humans at the doses used, combining them would be reasonable.
That "if" is doing the work. The mechanisms are described almost entirely in animal models, and mechanistic plausibility has a long history of not surviving human trials.
What the evidence actually is
BPC-157: a substantial rodent literature, much of it from a small number of research groups, showing accelerated healing across tendon, ligament, muscle, gut and nerve models. No published randomised human efficacy trials for injury repair. Oral and injected routes have both been studied in animals.
TB-500 / thymosin beta-4: thymosin beta-4 itself has been through human trials, but for indications such as dry eye and wound and cardiac repair rather than sports injury, with mixed results. TB-500 as sold is a fragment, not the full protein, and it does not carry those trials' data.
The combination has no human data. It also has no animal data as a combination — the pairing is an inference from two separate literatures, not a tested protocol.
This category is where I found four fabricated studies circulating in vendor marketing while researching peptide content. If you see a specific percentage improvement attributed to a named trial for this blend, the burden of proof is on finding that trial.
Dosing pattern and mixing
Commonly reported patterns are 250–500 mcg BPC-157 daily and 2–5 mg TB-500 weekly, often with a higher "loading" period for TB-500 followed by less frequent maintenance. These are community-reported ranges, not established protocols — there is no clinically validated dose because there are no clinical trials to set one.
The mismatch matters in a blend: a daily peptide and a weekly one in a fixed ratio have the same scheduling problem as the CJC-DAC blend. Many pre-mixed Wolverine vials are formulated at ratios intended for a roughly daily or every-other-day injection, which means the TB-500 accumulates differently than it would dosed separately.
Both peptides are stable in bacteriostatic water and are commonly reconstituted together, which is what the pre-mixed vial is.
How to track BPC-157 + TB-500 in Stackeddd
With no validated dose and no human efficacy data, what you log is the only evidence you will ever have about this one. Record the injury, the dose, the date you started, and a function measure you can repeat — range of motion, pain on a set movement, load tolerated. A subjective read six weeks later without a baseline is not a result.
Model it yourself · free, no account
Reconstitution Calculator
Two peptides in one vial means one reconstitution number drives both doses — worth getting right the first time rather than estimating.
Related compounds
Related reading: What peptides can you mix in the same syringe? · Peptide reconstitution math: how much BAC water to add
Frequently asked questions
What is the Wolverine stack?
The community name for BPC-157 combined with TB-500, sold either as two vials or as one pre-mixed blend. The name refers to the comic-book healing factor, which is a fair indication of how the combination is marketed rather than what has been demonstrated.
Is there human evidence for BPC-157 and TB-500?
Not for injury repair. Neither compound has published randomised human efficacy trials for that use. BPC-157 has a substantial rodent literature; thymosin beta-4 has human trials for other indications entirely. The combination has never been tested in humans, and has not been tested as a combination in animals either.
Why are BPC-157 and TB-500 combined?
Because their proposed mechanisms do not overlap — BPC-157 is associated with angiogenesis and tendon healing, TB-500 with actin regulation and cell migration. The logic is that one improves blood supply to a repair site while the other helps the repairing cells get there. It is a reasonable inference drawn from two separate animal literatures, not a tested protocol.
How is the blend usually dosed?
Commonly reported patterns are 250–500 mcg of BPC-157 daily and 2–5 mg of TB-500 weekly, often with a higher initial period for TB-500. These are community-reported figures, not validated protocols — there are no clinical trials from which to set a dose.
This is educational information, not medical advice. Doses and protocols above reflect published references and community practice — protocol decisions belong with your prescribing physician. Generic names used throughout. How this reference is built & how the AI is tested →
STACKEDDD
Track it instead of guessing.
Doses, reconstitution, bloodwork, and an AI coach grounded in your own data — free to start, on the App Store and Google Play.